Media.Player

Novel Therapies for Congestive Heart Failure

技術優勢

Targeted delivery of the therapeutic reagent to desired cells and tissues to treat cardiomyopathy and other cardiac diseases.

技術應用

Therapeutics for cardiac disease.

詳細技術說明

None

*Abstract

Congestive heart failure (CHF) is defined as abnormal heart function resulting in inadequate cardiac output for metabolic needs. Dr. Paul Grayburn, a cardiologist in Baylor Scott & White Research Institute, is a pioneer in the use of ultrasound targeted microbubble destruction (UTMD) technology to deliver therapeutic genes and proteins to treat cardiac disease. Our technology can reverse established Adriamycin (ADM) cardiomyopathy by stimulating myocardial regeneration in an in vivo rat model. It is a potential breakthrough for treating CHF. MarketCongestive heart failure (CHF) is defined as abnormal heart function resulting in inadequate cardiac output for metabolic needs. It has been reported that 3-4 million adults in the United States have CHF. Once symptoms of heart failure are moderately severe, the prognosis is worse than most cancers in that 50% of such patients are dead within 4 years. The global market for CHF pharmaceuticals was valued at nearly $11.2 billion in 2010. Present treatments for CHF include pharmacological therapies, coronary revascularization procedures (e.g. coronary artery bypass surgery and angioplasty), and implantable cardiac defibrillators and biventricular pacemakers. However, even with optimal therapy, approximately half of the patients with severe CHF die within 4 years. Cardiac transplantation provides a better solution, but is available for only 1 patient per 1000 with CHF. CHF affects people of all ages. It is very crucial to find new resource of cardiac muscle regeneration for CHF treatments. TechnologyUTMD-GLP-1. GLP-1 was successfully delivered through UTMD technology to rat heart cells with evidence that transfected cardiac cells had undergone proliferation. UTMD-GLP-1 gene therapy restored left ventricular (LV) mass, fractional shortening index, and LV posterior wall diameter. Undisclosed therapeutic agent. The protein can be used as a stand alone therapeutic agent. The gene can be delivered using UTMD technology. The technologies listed above have shown their function to stimulate myocardial regeneration and also reverse the cardiomyopathy itself in our in vivo rat model.

*Principal Investigation

Name: Paul Grayburn

Department:

國家/地區

美國